Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Amazon Explores AI Content Marketplace With Media Publishers 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
SAN DIEGO, March 13, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Phanes Therapeutics as a strategic partner to advance their oncology drug discovery pipeline.
|
|||
CrownBio provides the world’s largest collection of Patient-Derived Xenograft (PDX) models and is a leading provider of integrated oncology solutions that enable development of cutting-edge cancer treatments. Phanes will gain access to CrownBio’s clinically relevant CDX models, exclusive PDX models and robust in vitro assays to propel their innovative drug discovery pipeline.
Dr. Ming Wang, President and CEO of Phanes Therapeutics, expressed enthusiasm about this partnership, “We are an innovative drug discovery company with a robust pipeline and need access to top notch in vivo pharmacology efficacy models to quickly evaluate and advance our lead molecules. We are very glad to partner with CrownBio. They have very unique MuPrime™ models, as well as Humanized GEMMs (HuGEMM™) and Patient-Derived Xenograft (PDX) models for our oncology programs. We look forward to a productive partnership.”
“We are very pleased that Phanes Therapeutics has selected us as a trusted partner to advance their leading-edge oncology compounds,” said Laurie Heilmann, CrownBio’s Chief Business Officer. “Our unique capabilities will help Phanes efficiently and thoroughly assess drugs in their pipeline to identify and advance candidates showing the most promise for improved treatment of cancer.”
About Crown Bioscience Inc.
CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.
About Phanes Therapeutics
Phanes Therapeutics is a biotech company with strong innovative drug discovery and development programs in metabolic complications and oncology areas. It was founded by former Janssen/J&J Vice President Ming Wang, PhD, MBA. The company focuses exclusively on biologics drug discovery with multiple first-in-class and best-in-class molecules in its pipeline. For more information on Phanes, please visit www.phanesthera.com.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[email protected]
